Ovatech announced that its CEO, John A. Williams, will present at the upcoming “OneMedForum 2011” business development and finance conference for emerging healthcare and life science companies, to be held on January 11-13, 2011, in San Francisco at the Sir Francis Drake Hotel. Mr. Williams’
AUBURNDALE, MA, USA | January 5, 2011 | Ovatech, an emerging women’s health-focused company, announced today that its CEO, John A. Williams, will present at the upcoming “OneMedForum 2011” business development and finance conference for emerging healthcare and life science companies, to be held on January 11-13, 2011, in San Francisco at the Sir Francis Drake Hotel. Mr. Williams’ presentation will take place on Tuesday, Jan. 11, at 4:50 p.m. PST.
“the Ovaprene device is well-tolerated and acceptable to sexually active women and their partners.”
Ovaprene is a ‘one-size-fits-all’ patented, female-controlled, intravaginal organic silicone ring barrier-contraceptive that is designed to continuously release spermiostatic and spermicidal non-drug agents over a four-week period.
In a Phase 2 study, eighty-five (85) females participated and were instructed in the proper insertion of the one-size-fits-all Ovaprene ring at completion of menses—with removal at onset of subsequent menses; this protocol was observed once a month for three months for each study participant. All Ovaprene rings were retained in place, including post-coitus. To date, including Phase 1 data, 300+ post-coital tests of study-participants’ cervical pool have been analyzed, with zero motile sperm in the active ring study group. All participants were willing to use and recommend the product during sexual intercourse in the future, including their male partners. The final Phase 2 results were consistent with the preliminary Phase 2 data reported in May at the 2010 Annual Meeting of the American College of Obstetricians and Gynecologists (ACOG).
“Ovaprene is designed to be a completely new paradigm for birth control,” said John A. Williams, President and CEO of Ovatech. “We look forward to starting our Phase 3 pivotal trial in this new year.”
Ovaprene is designed to offer a non-systemic, female-controlled birth control option—without the need for partner consent or approval. Contraceptives and contraceptive devices are likely the most widely used medical devices in the world, with $22 billion spent on contraception in the U.S. market annually. In the U.S., 42 million women—or 7 in 10 women ages 15 to 44—are currently sexually active and do not want to become pregnant.
A Phase 1 safety-and-tolerability study concluded that “the Ovaprene device is well-tolerated and acceptable to sexually active women and their partners.” The study (“A Pilot Safety and Tolerability Study of a Non-Hormonal Vaginal Contraceptive Ring”) was published in The Journal of Reproductive Medicine.
Ovatech Inc., based in Auburndale, Mass., is an emerging medical technology company that is focused on products to enhance women’s health. In addition to Ovaprene, there are four additional, important products from the Company’s proprietary platform.
SOURCE: Ovatech Inc.
Post Views: 65
Ovatech announced that its CEO, John A. Williams, will present at the upcoming “OneMedForum 2011” business development and finance conference for emerging healthcare and life science companies, to be held on January 11-13, 2011, in San Francisco at the Sir Francis Drake Hotel. Mr. Williams’
AUBURNDALE, MA, USA | January 5, 2011 | Ovatech, an emerging women’s health-focused company, announced today that its CEO, John A. Williams, will present at the upcoming “OneMedForum 2011” business development and finance conference for emerging healthcare and life science companies, to be held on January 11-13, 2011, in San Francisco at the Sir Francis Drake Hotel. Mr. Williams’ presentation will take place on Tuesday, Jan. 11, at 4:50 p.m. PST.
“the Ovaprene device is well-tolerated and acceptable to sexually active women and their partners.”
Ovaprene is a ‘one-size-fits-all’ patented, female-controlled, intravaginal organic silicone ring barrier-contraceptive that is designed to continuously release spermiostatic and spermicidal non-drug agents over a four-week period.
In a Phase 2 study, eighty-five (85) females participated and were instructed in the proper insertion of the one-size-fits-all Ovaprene ring at completion of menses—with removal at onset of subsequent menses; this protocol was observed once a month for three months for each study participant. All Ovaprene rings were retained in place, including post-coitus. To date, including Phase 1 data, 300+ post-coital tests of study-participants’ cervical pool have been analyzed, with zero motile sperm in the active ring study group. All participants were willing to use and recommend the product during sexual intercourse in the future, including their male partners. The final Phase 2 results were consistent with the preliminary Phase 2 data reported in May at the 2010 Annual Meeting of the American College of Obstetricians and Gynecologists (ACOG).
“Ovaprene is designed to be a completely new paradigm for birth control,” said John A. Williams, President and CEO of Ovatech. “We look forward to starting our Phase 3 pivotal trial in this new year.”
Ovaprene is designed to offer a non-systemic, female-controlled birth control option—without the need for partner consent or approval. Contraceptives and contraceptive devices are likely the most widely used medical devices in the world, with $22 billion spent on contraception in the U.S. market annually. In the U.S., 42 million women—or 7 in 10 women ages 15 to 44—are currently sexually active and do not want to become pregnant.
A Phase 1 safety-and-tolerability study concluded that “the Ovaprene device is well-tolerated and acceptable to sexually active women and their partners.” The study (“A Pilot Safety and Tolerability Study of a Non-Hormonal Vaginal Contraceptive Ring”) was published in The Journal of Reproductive Medicine.
Ovatech Inc., based in Auburndale, Mass., is an emerging medical technology company that is focused on products to enhance women’s health. In addition to Ovaprene, there are four additional, important products from the Company’s proprietary platform.
SOURCE: Ovatech Inc.
Post Views: 65
